158 results about "Minocycline" patented technology

The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.

The method of the present application is directed towards a method for suppressing an allergic response in response to an allergic trigger. This method comprises the following steps; applying, topically, to an affected area an effective amount of a minocycline composition so that the minocycline composition contacts the affected area for an effective amount of time and removing the minocycline composition from the affected area.

Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

Topical minocycline compositions with reduced fluorescence are provided. In some instances, the compositions include an amount of a minocycline active agent associated with porous calcium particles. Also provided are methods of using the compositions, e.g., in the treatment of acne.

A sterilized medical device comprising minocycline and rifampin is described. The device is setrerilized by e-beam raditation such that degradation of minocycline and rifampin is minimized. Methods for sterilizing minocycline and rifampin-containing devices by e-beam radiation and methods of manufacturing devices, which methods include e-beam sterilization, are also described.

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (PTSD). In particular, described herein are angiotensin receptor blockers (ARBs), and in particular the combination of one or more ARB (such as telmisartan) and an agent that enhances the delivery of the ARB across the blood-brain barrier (such as minocycline). PTSD may be treated using a combination of telmisartan and minocycline at levels of each that are, by themselves, infective to treat PTSD. Also described herein are methods for treating PTSD by first identifying patents for whom the use of an ARB treatment would be effective, by determining that patient has a dysfunction in their angiotensin converting enzyme and/or other genes in the autonomic arousal axis.

The invention provides a method for preparing an absorbable and antibacterial guided tissue regeneration membrane for a bone-like structure, and belongs to the field of biological medical materials. The method comprises the following steps: firstly, preparing a cell free bovine pericardial collagen fiber membrane by adopting a repeated freeze-thaw method and a surface active agent TritonX-100, or preparing a demineralized cell free collagen fiber membrane of a cattle lamellar bone by using a method of EDTA decalcification by using the surfactant TritonX-100; treating by using sodium trimetaphosphate to obtain a phosphorylated collagen fiber membrane; with the assistance of a direct-current electric field, mineralizing in agar hydrogel containing calcium and phosphate, thereby obtaining a mineralized collagen membrane with a bone-like structure with certain hardness; and finally soaking the mineralized collagen membrane into a minocyline solution, and preparing an antibacterial bone-like structured composite membrane structure by virtue of the characteristics of combined minocyline and hydroxyapatite. The guided tissue regeneration membrane provided by the invention has a bone-like structure, is capable of maintaining a bone defect space, is good in operation forming property and antibacterial property, and can be applied to clinical practice for bone defect remediation and reconstruction in periodontal departments, dental implant mediation and occlusalf surfaces.

The invention relates to a novel preparation method for antibioticdrug tigecycline. 9-amino minocycline and N-tert-butyl group glycine are taken as starting materials. The novel preparation method is characterized in that the N-tert-butyl group glycine is dissolved in indifferent solvent, under the existence of an acidic acceptor and an amino acid condensating agent, reaction with 9-amino minocycline is carried out along the route of amino acid condensation for 3 hours to 10 hours, and then an indifferent solvent is cooled to a room temperature. Tigecycline is obtained through acidification, neutralization, extraction, drying, concentration and refining. In the preparation method disclosed by the invention, the operation is simplified, the purity of the obtained product reaches more than 99.5 percent, individual impurities are controlled to be lower than 0.1 percent, and an epimer is controlled to be lower than 0.5 percent; and the yield is high, the stability of the product is good, and the preparation method is suitable for industrial production.

The invention aims to provide minocycline hydroehloride sustained-release tablets with higher stability of medicament release and administrative safety, which are characterized by consisting of minocycline hydroehloride, a slow release material, a filler, a binder, a lubricating agent and a coating material. The minocycline hydroehloride sustained-release tablets have the characteristics of havingconvenient administration, lasting effect and stable curative effect, reducing untoward effect, improving the compliance of patients and the like.

Disclosed is a medicinal preparation for treating oral mucosa diseases comprising active medicinal constituents and auxiliary materials, which can be in the form of paster obtained through sheet pressing or thin films obtained through liquid phase film forming, the effective medicinal constituents can be antibiotic medicaments including Minocycline, hibitane, fortimicin, achromycin or metronidazole, the auxiliary materials include binding agent, disintegrating agent and flavoring agent.

The present invention relates to a kind of preparation of medicinal compound, particularly a kind of preparation method of cefminox sodium. The present invention adopts a synthesis route using 7-ACA as a starting material, and the cost of raw materials is lower than that of a synthesis route using 7-MAC as a starting material. The new synthetic route uses dichloroacetyl chloride instead of bromoacetyl bromide, which reduces the toxicity and cost of raw materials. The new synthetic route increases the intermediate treatment process, reduces the amount of impurities brought by the intermediate into the next reaction, and improves the quality and stability of the finished product. The present invention overcomes the shortcomings of the synthetic route using 7-MAC as the starting material through the above improvements.

The invention discloses a lipidosome-based method for modifying a PEEK (polyetheretherketone) surface with hexadecadrol/minocycline and an application of the method. Lipidosome loaded with hexadecadrol and minocycline is prepared with a thin film dispersion method and then modifies the PEEK surface. The method comprises following steps: (1), hexadecadrol and lipids are dissolved in a methanol and chloroform mixture (1:1, v/v); (2), methanol and chloroform are removed by a rotary vacuum evaporator, and then a lipid membrane is hydrated by a hydration solution; lipidosome loaded with hexadecadrol is obtained by water bath ultrasonic treatment, and is extruded by a porous polycarbonate membrane; dialysis is performed overnight; (3), lipidosome is mixed with a minocycline storage solution, the mixture is shaken, and lipidosome loaded with hexadecadrol/minocycline is obtained, and is stored for standby application at 4 DEG C after being dialyzed overnight; (4), PEEK implant is put in a dopamine solution for reaction, and ultrasonic cleaning is performed; (5), the PEEK implant is added to a hexadecadrol/minocycline lipidosome solution for soaking and is slightly cleaned, and a product is obtained. The obtained product can promote bone repair, regeneration and integration.

Oriented resorbable implants made from poly-4-hydroxybutyrate (P4HB) and copolymers thereof, have been developed that contain one or more antimicrobial agents to prevent colonization of the implants, and reduce or prevent the occurrence of infection following implantation in a patient. These oriented implants are particularly suitable for use in procedures where prolonged strength retention is necessary and there is a risk of infection. Coverings and receptacles made from poly-4-hydroxybutyrate and copolymers thereof, containing antimicrobial agents, have also been developed for use with implantable devices to prevent colonization of these devices, and to reduce or prevent the occurrence of infection following implantation of these devices in a patient. These coverings and receptacles may be used to hold, or partially or fully cover, devices such as pacemakers and neurostimulators. Preferably, the coverings and receptacles are made from meshes, non-wovens, films, fibers, and foams, and contain rifampin and minocycline.

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

Topical compositions for dermatological use are described. The topical compositions generally comprise a selective retinoid, such as tazarotene or adapalene, and/or a tetracycline-class antibiotic, such as minocycline or doxycycline, and a monohydric aliphatic alcohol. The compositions may further comprise a divalent cation, such as magnesium, calcium, or zinc, and an antioxidant, such as a sulfite or a thiosulfate. The composition may further comprise a carboxylate ester solvent.